

Does the patient reside in a nursing home?

Is the patient receiving or eligible for hospice services?

Is the patient's chronic pain associated with cancer or cancer treatment?

IF YES TO ONE OF THE ABOVE QUESTIONS, MAY PROCEED TO SIGNATURE AND DATE

## ~Long-Acting Opioid~ Prior Authorization Request Form

In order for members to receive Medicaid coverage for medications that require prior authorization, the prescriber must complete and fax this form to Optum. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information. For guestions, please contact the Optum help desk at 1-844-679-5363.

	ing physician:	Beneficiary:			
e:		Name:			
ĺ	ın NPI:	Medicaid ID#:			
alt	y:	Date of Birth:	Sex:		
one#:		Pharmacy Name	·		
:_		Pharmacy NPI:	Pharmacy Fax:		
es	e: Person at Office:	Pharmacy Phone:	Pharmacy Fax:		
	Opioid Regimen: Please include drug(s) reques	ted, strength, route, frequ	ency, and duration of use:		
2.	Diagnosis or Indication for Use:				
3.	Has the member previously tried any of the following preferred medications?				
٠.	has the member previously they ally of the for	lowing preferred medicat	OUS		
ο.	Check all that apply:		eck all that apply		
Э.		Response, ch			
ο.	Check all that apply:	Response, ch	eck all that apply		
3.	Check all that apply:  ☐ Butrans Transdermal System	Response, ch	eck all that apply  ☐ non-response ☐allergy		
Э.	Check all that apply:  ☐ Butrans Transdermal System  ☐ Fentanyl Patches  ☐ Morphine Sulfate CR 12 Hr Tablet	Response, ch	eck all that apply  □ non-response □allergy □ non-response □allergy □ non-response □allergy		
	Check all that apply:  ☐ Butrans Transdermal System  ☐ Fentanyl Patches	Response, ch	eck all that apply  □ non-response □allergy □ non-response □allergy □ non-response □allergy		
	Check all that apply:  ☐ Butrans Transdermal System  ☐ Fentanyl Patches  ☐ Morphine Sulfate CR 12 Hr Tablet	Response, ch	eck all that apply  □ non-response □allergy □ non-response □allergy □ non-response □allergy		
· .	Check all that apply:  □ Butrans Transdermal System  □ Fentanyl Patches  □ Morphine Sulfate CR 12 Hr Tablet  For tramadol products, has the member previous	Response, ch	eck all that apply  non-response allergy non-response allergy non-response allergy referred medication?		
	Check all that apply:  □ Butrans Transdermal System □ Fentanyl Patches □ Morphine Sulfate CR 12 Hr Tablet  For tramadol products, has the member previous Check if applicable:	Response, ch	eck all that apply  non-response allergy non-response allergy non-response allergy eferred medication? eck all that apply:		

YES

YES

YES

NO

NO

NO

Non-Opioid alternatives (up to a maximum dose recommended by the FDA) have been considered, and any appropriate treatments are documented in the patient's medical records. Such treatments may include, but are not limited to: NSAIDs, Acetaminophen.	YES	NO
Non-Pharmacological Treatments have been considered, and any appropriate treatments are documented in the patient's medical records. Such treatments may include, but are not limited to: Acupuncture, Chiropractic, Physical Therapy.	YES	NO
Vermont Prescription Monitoring System (VPMS) has been queried.	YES	NO
Patient education and informed consent have been obtained, and a Controlled Substance Treatment Agreement is included in the patient's medical record.	YES	NO
A reevaluation of the effectiveness and safety of the patient's pain management plan, including an assessment of the patient's adherence to the treatment regimen is completed no less than once every 90 days.	YES	NO
Patient has a valid prescription for or states they are in possession of naloxone.	YES	NO

Prescriber's Signature:Date	<b>:</b>	
By completing this form, I hereby certify that the above request is true, accurate and complete. That the request is medically necessar clinically supported in the patient's medical records. I also understand that any misrepresentations or concealment of any information to audit and/or recoupment.	•	
Other Information/ Comments:		
Patient has a valid prescription for or states they are in possession of naloxone.	YES	NO
an assessment of the patient's adherence to the treatment regimen is complete once every 90 days.	ed no less than	